IASLC 2016 Coverage
PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.
Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).
Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC
Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).
Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC
First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).
Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control
Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.
The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.
Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).
Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.
Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).
Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.
The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.
Controlling tobacco use is vital to managing the threat it poses to public health, but doing so requires a multi pronged approach.
Although smoking is clearly a major risk factor, pathogenic viruses acquired from consumption of red meat may be a synergistic causative factor.
Cabozantinib demonstrated safety and efficacy for treating patients with RET-rearranged lung cancer in an open-label, phase 2 trial.
A randomized phase 2 study found that 30 Grays (Gy) in 1 fraction is equivalent to 60 Gy in 3 fractions in terms of toxicity and survival.
Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over demonstrated a progression-free survival (PFS) benefit.
Double mutations do not significantly decrease overall survival (OS), but do alter progression-free survival (PFS) under first line treatment.
Brigatinib has shown substantial clinical activity among patients with ALK-positive non-small cell lung cancer (NSCLC) who have brain metastases.
A high percentage of patients with limited-stage small cell lung cancer (SCLC) are elderly, but there is a lack of data concerning the efficacy and safety.
Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|